Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amantadine extended-release for levodopa-induced dyskinesia in Parkinson's disease
2014-001131-36Phase 3Suspended
- Sponsor
- Osmotica Pharmaceuticals
- Start
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Amantadine hydrochloride extended-release with Placebo (2 arms). Started Sep 2014; status: suspended.
02
Drugs
amantadine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2014-001131-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001131-36.